Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
AVAILABLE
NCT06797362

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Sponsor: Nuvalent Inc.

View on ClinicalTrials.gov

Summary

The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.

Official title: Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

EXPANDED_ACCESS

Enrollment

Not specified

Start Date

Not specified

Completion Date

Not specified

Last Updated

2026-05-28

Healthy Volunteers

Not specified

Interventions

DRUG

NVL-520

Oral tablet

Locations (36)

University of Colorado Anschutz School of Medicine

Aurora, Colorado, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

Manhattan, New York, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Washington / Fred Hutchinson Cancer Center

Seattle, Washington, United States

Chris O'Brien Lifehouse

Camperdown, New South Wales, Australia

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

UZLeuven

Leuven, Belgium

Cross Cancer Institute

Edmonton, Alberta, Canada

Princess Margaret Hospital

Toronto, Ontario, Canada

Centre Leon Berard

Lyon, Auvergne-Rhône-Alpes, France

GCS IUCT Oncopole

Toulouse, Occitanie, France

CHU de Nantes

Nantes, Pays de la Loire Region, France

Institut Gustave Roussy

Villejuif, Île-de-France Region, France

IRCCS Istituto Tumori Giovanni Paolo II

Bari, Italy

L'Istituto Europeo di Oncologia S.r.l.

Milan, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

IRCCS Istituto Oncologico Veneto

Padova, Italy

AUSL della Romagna - Ravenna

Ravenna, Italy

Istituto Nazionale Tumori "Regina Elena

Roma, Italy

Antoni van Leeuwenhoek Hospital

Amsterdam, Netherlands

Netherlands Cancer Institute: NKI

Amsterdam, Netherlands

University Medical Center Groningen

Groningen, Netherlands

National University Hospital Singapore

Singapore, Singapore

National Cancer Centre Singapore

Singapore, Singapore

Uomi Cancer Center-Clinica Tres Torres

Barcelona, Spain

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Gregorio Marañón General University Hospital

Madrid, Spain

Hospital Univ Doce de Octubre

Madrid, Spain

National Cheng Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

The Royal Marsden Hospital

Sutton, Surrey, United Kingdom

The Royal Marsden Hospital

London, United Kingdom

The Christie Hospital

Manchester, United Kingdom